Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 313

Sort by

Sort Order Select

Journal Articles

Real world test characteristics of mass spectrometry monoclonal protein monitoring in multiple myeloma

Kevin Shim, Mariano Arribas, Fabio Samir Vargas Cely, Udit Yadav, J Wiedmeier-Nutor, Nathan Punwani, Gabriela Alatorre, Sharene Best, Katalin Kelemen, Saurabh Chhabra, P. Leif Bergsagel, David Murray, Rafael Fonseca

Blood (2025) 146 (Supplement 1): 2201.

https://doi.org/10.1182/blood-2025-2201

Published: 2025

Journal Articles

Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma

Blood (2025) 146 (Supplement 1): 2178.

https://doi.org/10.1182/blood-2025-2178

Published: 2025

Journal Articles

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Blood (2025) 146 (Supplement 1): 686.

https://doi.org/10.1182/blood-2025-686

Published: 2025

Journal Articles

Targeting lysosomes to overcome albumin-mediated proteasome inhibitor resistance in multiple myeloma

Sinto Chirackal, Gregory Ahmann, Esteban Braggio, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca

Blood (2025) 146 (Supplement 1): 2139.

https://doi.org/10.1182/blood-2025-2139

Published: 2025

Journal Articles

Radiomics-based identification of high-risk disease in newly diagnosed multiple myeloma

Guneet Janda, Emmanuel Contreras Guzman, Michael Howe, Jacob Shreve, Surendra Dasari, Nadine Abdallah, Wilson Gonsalves, Francis Buadi, Joselle Cook, Taxiarchis Kourelis, Suzanne Hayman, Morie Gertz, Rafael Fonseca, Angela Dispenzieri, S. Vincent Rajkumar, Matthew Thorpe, Shaji Kumar, Moritz Binder

Blood (2025) 146 (Supplement 1): 924.

https://doi.org/10.1182/blood-2025-924

Published: 2025

Journal Articles

Prophylactic dexamethasone to reduce risk of cilta-cel associated immune effector cell delayed neurotoxicity

Blood (2025) 146 (Supplement 1): 5953.

https://doi.org/10.1182/blood-2025-5953

Published: 2025

Journal Articles

Cyclin D1 beyond the cell cycle: A new role in t(11;14) multiple myeloma

Blood (2025) 146 (Supplement 1): 3939.

https://doi.org/10.1182/blood-2025-3939

Published: 2025

Journal Articles

Comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus belantamab mafodotin (belamaf), bortezomib, and dexamethasone and versus belamaf, pomalidomide, and dexamethasone in patients with relapsed / refractory multiple myeloma (RRMM) previously treated with 1–3 prior lines of therapy using a matching-adjusted indirect comparison

Christopher Strouse, Surbhi Sidana, Rafael Fonseca, Joaquin Martinez-Lopez, Yaël Cohen, Binod Dhakal, Murali Janakiram, Suzy Van Sanden, João Mendes, Joris Diels, Seina Lee, Sundar Jagannath

Blood (2025) 146 (Supplement 1): 4046.

https://doi.org/10.1182/blood-2025-4046

Published: 2025

Journal Articles

Real-world (RW) outcomes of newly diagnosed multiple myeloma (NDMM) patients (pts) treated with front-line daratumumab (dara), bortezomib (bor), lenalidomide (len) and dexamethasone (dex) (DVRd)

Blood (2025) 146 (Supplement 1): 4585.

https://doi.org/10.1182/blood-2025-4585

Published: 2025

Journal Articles

Characteristics of patients with Relapsed/Refractory multiple myeloma (RRMM) in europe and the US

Binod Dhakal, Victoria Benson, Astrid McKeown, Linda Kalilani, Amber Simpson, Amanda Ribbands, Annabel Lambert, Rafael Fonseca

Blood (2025) 146 (Supplement 1): 7515.

https://doi.org/10.1182/blood-2025-7515

Published: 2025

Journal Articles

Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies

Blood (2025) 146 (Supplement 1): 5772.

https://doi.org/10.1182/blood-2025-5772

Published: 2025

Journal Articles

Comparative analysis of next generation flow (NGF) and next generation sequencing based clonoseq for MRD detection in multiple myeloma using paired bone marrow samples

J Wiedmeier-Nutor, Mariano Arribas, Karl Franke, Juana Figueroa Aguirre, Katalin Kelemen, Udit Yadav, P. Leif Bergsagel, Saurabh Chhabra, Rafael Fonseca

Blood (2025) 146 (Supplement 1): 4020.

https://doi.org/10.1182/blood-2025-4020

Published: 2025

Journal Articles

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Blood (2025) 146 (13): 1575–1585.

https://doi.org/10.1182/blood.2024028107

Published: 2025

Includes: Supplemental data

Journal Articles

Pre-Infusion Ferritin: A Predictive Biomarker for CAR T-Cell Therapy Response in Multiple Myeloma

Eider Moreno, Mariano Arribas, David A. Martinez, Juana Figueroa Aguirre, Rohan S Patel, Udit Yadav, Erin J Wiedmeier-Nutor, Leif Bergsagel, Rafael Fonseca, Saurabh Chhabra, Januario E. Castro

Blood (2024) 144 (Supplement 1): 7096.

https://doi.org/10.1182/blood-2024-211376

Published: 2024

Journal Articles

A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma

J Erin Wiedmeier-Nutor, Surendra Dasari, Richard Kumaran Kandasamy, Kiran Manalaparthi, Laura Ann Bruins, Gregory Ahmann, Mariano Arribas, P. Leif Bergsagel, Akhilesh Pandey, Esteban Braggio, Rafael Fonseca

Blood (2024) 144 (Supplement 1): 3269.

https://doi.org/10.1182/blood-2024-206239

Published: 2024

Journal Articles

Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

Blood (2024) 144 (Supplement 1): 4685.1.

https://doi.org/10.1182/blood-2024-208457

Published: 2024

Journal Articles

Efficacy of Carvykti in Cartitude-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting

Rafael Fonseca, Joris Diels, Francesca Ghilotti, João Mendes, Teresa Hernando, Seina Lee, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Winfried Alsdorf, Margherita Ursi

Blood (2024) 144 (Supplement 1): 2005.

https://doi.org/10.1182/blood-2024-201583

Published: 2024

Journal Articles

Venetoclax in Patients with Multiple Myeloma with or without t(11;14): A Real-World Analysis

Edward R Scheffer Cliff, Martin F Kaiser, Douglas W. Sborov, Rafael Fonseca, Ghulam Rehman Mohyuddin

Blood (2024) 144 (Supplement 1): 3792.6.

https://doi.org/10.1182/blood-2024-207365

Published: 2024

Journal Articles

Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada

Alissa Visram, Rajshekhar Chakraborty, Gregory R Pond, Hsien Seow, Anastasia Gayowsky, Ghulam Rehman Mohyuddin, Samer Al Hadidi, Alejandro Garcia-Horton, Rafael Fonseca, Hira Mian

Blood (2024) 144 (Supplement 1): 5170.3.

https://doi.org/10.1182/blood-2024-200956

Published: 2024

Journal Articles

Cyclin D1 Induces Global Epigenetic and Transcriptional Changes in Multiple Myeloma with t(11;14)(q13;q32)

Huihuang Yan, Suganti Shivaram, Hongwei Tang, Hans Anderson, Shulan Tian, Michael D Howe, Abiola Bolarinwa, Cinthya Zepeda Mendoza, Stacey Lehman, Leif Bergsagel, Esteban Braggio, Rafael Fonseca, Shaji Kumar, Francesco Maura, Linda B. Baughn

Blood (2024) 144 (Supplement 1): 6822.

https://doi.org/10.1182/blood-2024-208503

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real world test characteristics of mass spectrometry monoclonal protein monitoring in multiple myeloma

Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Targeting lysosomes to overcome albumin-mediated proteasome inhibitor resistance in multiple myeloma

Radiomics-based identification of high-risk disease in newly diagnosed multiple myeloma

Prophylactic dexamethasone to reduce risk of cilta-cel associated immune effector cell delayed neurotoxicity

Cyclin D1 beyond the cell cycle: A new role in t(11;14) multiple myeloma

Real-world (RW) outcomes of newly diagnosed multiple myeloma (NDMM) patients (pts) treated with front-line daratumumab (dara), bortezomib (bor), lenalidomide (len) and dexamethasone (dex) (DVRd)

Characteristics of patients with Relapsed/Refractory multiple myeloma (RRMM) in europe and the US

Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies

Comparative analysis of next generation flow (NGF) and next generation sequencing based clonoseq for MRD detection in multiple myeloma using paired bone marrow samples

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Pre-Infusion Ferritin: A Predictive Biomarker for CAR T-Cell Therapy Response in Multiple Myeloma

A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma

Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

Efficacy of Carvykti in Cartitude-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting

Venetoclax in Patients with Multiple Myeloma with or without t(11;14): A Real-World Analysis

Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada

Cyclin D1 Induces Global Epigenetic and Transcriptional Changes in Multiple Myeloma with t(11;14)(q13;q32)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only